Professional paper

https://doi.org/10.20471/acc.2022.61.s3.12

Systemic Triple Therapy in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Tomislav Omrčen orcid.org/0000-0002-7656-7877 ; Department of Oncology and Radiotherapy, University Hospital Split, Split, Croatia; School of Medicine, University of Split, Split, Croatia

Abstract

For many years, androgen deprivation therapy (ADT) as monotherapy has been the
gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Several studies
have been published within the last decade demonstrating a significant survival advantage resulting
from combining the treatment with standard ADT plus docetaxel or androgen receptor targeted
therapy (ARTA) compared to ADT monotherapy. Recently published data of the PEACE-1 and
ARASENS trials suggest that in the future, triple therapy might be a treatment option for patients
with mHSPC.

Keywords

Hormone-sensitive Prostate Cancer; Systemic Therapy; Novel Hormonal Therapy; Taxanes; Triple Therapy

Hrčak ID:

286376

URI

https://hrcak.srce.hr/286376

Publication date:

1.10.2022.

Article data in other languages: croatian

Visits: 2.317 *